


Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**
 (Use as many sheets as necessary)



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
 Approved for use through 10/31/2002. OMB 051-0031
 US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known

Application Number	09/524454
Filing Date	March 10, 2000
First Named Inventor	Berg, Kristian
Group Art Unit	1644
Examiner Name	Ewoldt, Gerald

Sheet 1 of 2

Attorney Docket No: 90024.013US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
--------------------	---------------------	------------------	---	-------	----------	----------------------------

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²
SPZ	WO 93/14142	07/22/1993	Kopecek, Jindrich, et al			
	WO 95/03814	02/09/1995	Edelson, Richard L., et al			
	WO 96/07432	03/14/1996	Berg, Kristian, et al			

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		DOUGHERTY, THOMAS.J., et al. "REVIEW", <u>Photodynamic Therapy: Journal of the National Cancer Institute</u> , Vol. 90, No. 12, (June 17, 1998), 889-905	✓
		GERMAIN, RONALD.N. "MHC-Dependent Antigen Processing and Peptide Presentation: Providing Ligands for T Lymphocyte Activation", <u>Cell</u> , Vol. 76, Lymphocyte Biology Section, (January 28, 1994), 287-299	✓
		HANLON, DOUGLAS.J., et al. "Photoactivated 8-Methoxypsoralen Treatment Causes a Peptide-Dependent Increase in Antigen Display by Transformed Lymphocytes", <u>Publication of the International Union Against Cancer; Int. J. Cancer</u> ; 78, XP-000946568, (January 12, 1998), 70-75	✓
		KIRKIN, ALEXEI.F., et al. "Establishment of gp100 and MART-1/Melan-A-specific cytotoxic T lymphocyte clones using in vitro immunization against preselected highly immunogenic melanoma cell clones", <u>Cancer Immunol Immunother</u> , Springer-Verlag 1999, Received December 16, 1988/Accepted March 23, 1999, (1999), 239-246	✓
		ROCK, KENNETH.L., et al. "A new foreign policy: MHC class I molecules monitor the outside world", <u>Review Immunology Today</u> , Vol. 17, (March, 1996), 131-137	✓
		SCHULER, G., et al. "Commentary: Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors", <u>Department of Dermatology; University of Erlangen-Nurnberg; XP-002148419</u> , J. Exp. Med The Rockefeller University Press; Vol. 186, Number 8, (October 20, 1997), 1183-1187	✓
		SPECHT, JENNIFER.M., et al. "Dendritic Cells Retrovirally Transduced with a Model Antigen Gene Are Therapeutically Effective Against Established Pulmonary Metastases", <u>The Journal of Experimental Medicine</u> , Volume 186, Number 8, (October 20, 1997), 1213-1221	✓
SPZ		YEWDELL, JONATHAN.W., et al. "Cell Biology of Antigen Processing and Presentation to Major Histocompatibility Complex Class I Molecule-Restricted T Lymphocytes", <u>Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases</u> , <u>Advances in Immunology</u> , Vol. 52, (1992), 1123	

EXAMINER

Ewoldt

DATE CONSIDERED

2/5/03